Summary & Overview
HCPCS J9275: Injection of cosibelimab-ipdl, 2 mg
HCPCS Level II code J9275 identifies the injectable biologic cosibelimab-ipdl, dosed per 2 mg units. As a HCPCS Level II drug code, it is used on medical claims to report administration of this specialty immunotherapy agent in outpatient infusion centers or oncology clinics. Accurate reporting of J9275 is important for clinical documentation, claims processing, and national monitoring of biologic therapy utilization.
Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context of cosibelimab-ipdl, billing considerations tied to HCPCS Level II drug coding, and the payer landscape relevant to coverage and claims adjudication. The publication outlines typical sites of service and the service type associated with the code, and summarizes the elements readers can expect such as benchmarking of reimbursement practices, policy updates affecting HCPCS drug codes, and clinical indications tied to biologic infusion workflows.
Data not available in the input for payer-specific rates, associated taxonomies, and ICD-10 diagnosis mappings. The coverage focuses on national implications for coding and billing practice rather than state-level policy.
Billing Code Overview
HCPCS Level II code J9275 represents an injection of cosibelimab-ipdl, 2 mg. The service type is drug administration (injectable biologic). The typical site of service for this HCPCS Level II drug administration is outpatient infusion or oncology clinic, where specialty biologic injections are commonly provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a metastatic or unresectable malignancy for which PD-L1 pathway inhibition with cosibelimab-ipdl is indicated. The patient presents to an outpatient oncology infusion center or hospital outpatient department for administration of J9275 (injection, cosibelimab-ipdl, 2 mg). The clinical workflow includes medication verification by the oncology pharmacist, baseline vitals and laboratory review (including liver function tests, thyroid studies, and complete blood count), verification of recent imaging and oncologist order, informed consent discussion documented in the medical record, placement of an IV or use of existing central venous access, administration of the dose per protocol with monitoring for infusion-related or immune-mediated adverse events, and post‑infusion observation. Documentation captures the specific drug and dose administered (J9275 units corresponding to the milligrams given), start and stop times, lot number, and any immediate reactions. Typical sites of service are outpatient infusion center, hospital outpatient department, or physician office with chemotherapy administration capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified |